Shares of bluebird bio (NASDAQ: BLUE) fell over 13% last month, according to data provided by S&P Global Market Intelligence. After rising for all of 2017 and earning a market cap as high as $10 billion earlier this year, investors are beginning to lose enthusiasm for the company's approach to developing living medicines. While the biopharma and its partner Celgene have a promising pipeline of drugs, the swift pace of innovation in biopharma may reduce the market potential quicker than analysts previously expected.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,